fda compounding semaglutide warning november 2025 Drug compounders sue over declaration ending Wegovy shortage FDA Warns on Certain Forms

Compounded semaglutide uses the identical active pharmaceutical ingredient as Wegovy, but is prepared on an individual basis by state-licensed 503A compounding pharmacies

Discontinuing semaglutide results in a gradual decline in therapeutic benefits over several weeks as the medication is eliminated from the body

This is compared to only 2.4% weight loss in those who only made lifestyle changes

Evasive or unclear responses suggest problems

These are trial averages under study conditions, not guaranteed outcomes

Many researchers transition from their peak dose to a lower maintenance level rather than stopping entirely